Claris Lifesciences underwent an audit by the USFDA for pharmacovigilance in the last week of May and has not received any observation.
“Claris Lifesciences along with its wholly-owned subsidiary Claris Injectables Ltd announced today that it underwent a successful USFDA Pharmacovigilance (PV) audit from May 29-31 with no observation (i483s),” the company said in a BSE filing today.
The company shares were trading up by 4.34 per cent at Rs 341.25 on the BSE.
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.